심장재동기화치료 시스템 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Cardiac Resynchronization Therapy Systems Market (Product Type: Cardiac Resynchronization Therapy Pacemaker and Cardiac Resynchronization Therapy Defibrillator) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

US $ 5,795 ￦ 8,630,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 13,098,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,566,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

심장재동기화치료 시스템 시장 - 보고서 범위

TMR의 세계 심장재동기화치료 시스템 시장 보고서는 과거와 현재의 성장 동향과 2023-2031년 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻을 수 있는 기회를 조사합니다. 이 보고서는 2017-2031년 기간 동안 세계 심장재동기화치료 시스템 시장의 수익을 제공하며, 2023년을 기준 연도로, 2031년을 예측 연도로 간주합니다. 또한 2023-2031년 세계 심장재동기화치료 시스템 시장의 복합 연간 성장률(CAGR %)도 제공합니다.

이 보고서는 광범위한 연구를 통해 작성되었습니다. 1차 조사에서는 분석가들이 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 인터뷰하여 주요 연구 활동의 대부분을 수행했으며, 2차 조사에서는 심장재동기화치료 시스템 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서 참조를 포함합니다.

이 보고서는 세계 심장재동기화치료 시스템 시장의 경쟁 환경에 대해 자세히 조사하고 있습니다. 세계 심장재동기화치료 시스템 시장에서 활동하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성 측면에서 프로파일링되었습니다. 회사 프로필, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 심장재동기화치료 시스템 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 소개
• 개요
• 시장 역학
• 세계 시장 분석과 예측(2017-2031년)

제5장 중요한 인사이트

• 파이프라인 분석
• 주요 제품/브랜드 분석
• 주요 인수합병
• COVID-19 팬데믹이 업계에 미치는 영향

제6장 세계 시장 분석과 예측 : 제품 유형별

• 소개와 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 제품 유형별(2017-2031년)
  • 심장재동기화치료 페이스메이커
  • 심장재동기화치료 제세동기
• 시장 매력도 분석 : 제품 유형별

제7장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 금액 예측 : 지역별(2017-2031년)
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력도 분석 : 지역별

제8장 북미 시장 분석과 예측

제9장 유럽 시장 분석과 예측

제10장 아시아태평양 시장 분석과 예측

제11장 라틴아메리카 시장 분석과 예측

제12장 중동 및 아프리카 시장 분석과 예측

제13장 경쟁 상황

• 시장 기업 : 경쟁 매트릭스(기업 계층·규모별)
• 시장 점유율 분석 : 기업별(2022년)
• 기업 개요
  • Medtronic
  • Boston Scientific Corporation
  • Abbott
  • LivaNova PLC
  • BIOTRONIK SE &Co. KG
  • Asahi Kasei Medical Co., Ltd.
  • NIHON KOHDEN CORPORATION
  • Schiller AG

ksm

영문 목차

영문목차

Cardiac Resynchronization Therapy Systems Market - Scope of Report

TMR's report on the global cardiac resynchronization therapy systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiac resynchronization therapy systems market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiac resynchronization therapy systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cardiac resynchronization therapy systems market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiac resynchronization therapy systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiac resynchronization therapy systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiac resynchronization therapy systems market.

The report delves into the competitive landscape of the global cardiac resynchronization therapy systems market. Key players operating in the global cardiac resynchronization therapy systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiac resynchronization therapy systems market profiled in this report.

Key Questions Answered in Global cardiac resynchronization therapy systems Market Report:

• What is the sales/revenue generated by cardiac resynchronization therapy systems across all regions during the forecast period?
• What are the opportunities in the global cardiac resynchronization therapy systems market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cardiac Resynchronization Therapy Systems Market - Research Objectives and Research Approach

The comprehensive report on the global cardiac resynchronization therapy systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cardiac resynchronization therapy systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiac resynchronization therapy systems market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cardiac Resynchronization Therapy Systems Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, by Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product Type, 2017-2031
  • 6.3.1. Cardiac Resynchronization Therapy Pacemaker
  • 6.3.2. Cardiac Resynchronization Therapy Defibrillator
• 6.4. Market Attractiveness Analysis, by Product Type

7. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, by Region

• 7.1. Key Findings
• 7.2. Market Value Forecast, by Region, 2017-2031
  • 7.2.1. North America
  • 7.2.2. Europe
  • 7.2.3. Asia Pacific
  • 7.2.4. Latin America
  • 7.2.5. Middle East & Africa
• 7.3. Market Attractiveness Analysis, by Region

8. North America Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

• 8.1. Introduction
• 8.2. Key Findings
• 8.3. Market Value Forecast, by Product Type, 2017-2031
  • 8.3.1. Cardiac Resynchronization Therapy Pacemaker
  • 8.3.2. Cardiac Resynchronization Therapy Defibrillator
• 8.4. Market Value Forecast, by Country, 2017-2031
  • 8.4.1. U.S.
  • 8.4.2. Canada
• 8.5. Market Attractiveness Analysis
  • 8.5.1. By Product Type
  • 8.5.2. By Country

9. Europe Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

• 9.1. Introduction
• 9.2. Key Findings
• 9.3. Market Value Forecast, by Product Type, 2017-2031
  • 9.3.1. Cardiac Resynchronization Therapy Pacemaker
  • 9.3.2. Cardiac Resynchronization Therapy Defibrillator
• 9.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 9.4.1. Germany
  • 9.4.2. U.K.
  • 9.4.3. France
  • 9.4.4. Italy
  • 9.4.5. Spain
  • 9.4.6. Rest of Europe
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Product Type
  • 9.5.2. By Country/Sub-region

10. Asia Pacific Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Product Type, 2017-2031
  • 10.3.1. Cardiac Resynchronization Therapy Pacemaker
  • 10.3.2. Cardiac Resynchronization Therapy Defibrillator
• 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.4.1. China
  • 10.4.2. Japan
  • 10.4.3. India
  • 10.4.4. Australia & New Zealand
  • 10.4.5. Rest of Asia Pacific
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Product Type
  • 10.5.2. By Country/Sub-region

11. Latin America Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Product Type, 2017-2031
  • 11.3.1. Cardiac Resynchronization Therapy Pacemaker
  • 11.3.2. Cardiac Resynchronization Therapy Defibrillator
• 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.4.1. Brazil
  • 11.4.2. Mexico
  • 11.4.3. Rest of Latin America
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Product Type
  • 11.5.2. By Country/Sub-region

12. Middle East & Africa Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Product Type, 2017-2031
  • 12.3.1. Cardiac Resynchronization Therapy Pacemaker
  • 12.3.2. Cardiac Resynchronization Therapy Defibrillator
• 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.4.1. GCC Countries
  • 12.4.2. South Africa
  • 12.4.3. Rest of Middle East & Africa
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Product Type
  • 12.5.2. By Country/Sub-region

13. Competition Landscape

• 13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 13.2. Market Share Analysis, by Company (2022)
• 13.3. Company Profiles
  • 13.3.1. Medtronic
    • 13.3.1.1. Company Overview
    • 13.3.1.2. Product Portfolio
    • 13.3.1.3. SWOT Analysis
    • 13.3.1.4. Financial Overview
    • 13.3.1.5. Strategic Overview
  • 13.3.2. Boston Scientific Corporation
    • 13.3.2.1. Company Overview
    • 13.3.2.2. Product Portfolio
    • 13.3.2.3. SWOT Analysis
    • 13.3.2.4. Financial Overview
    • 13.3.2.5. Strategic Overview
  • 13.3.3. Abbott
    • 13.3.3.1. Company Overview
    • 13.3.3.2. Product Portfolio
    • 13.3.3.3. SWOT Analysis
    • 13.3.3.4. Financial Overview
    • 13.3.3.5. Strategic Overview
  • 13.3.4. LivaNova PLC
    • 13.3.4.1. Company Overview
    • 13.3.4.2. Product Portfolio
    • 13.3.4.3. SWOT Analysis
    • 13.3.4.4. Financial Overview
    • 13.3.4.5. Strategic Overview
  • 13.3.5. BIOTRONIK SE & Co. KG
    • 13.3.5.1. Company Overview
    • 13.3.5.2. Product Portfolio
    • 13.3.5.3. SWOT Analysis
    • 13.3.5.4. Financial Overview
    • 13.3.5.5. Strategic Overview
  • 13.3.6. Asahi Kasei Medical Co., Ltd.
    • 13.3.6.1. Company Overview
    • 13.3.6.2. Product Portfolio
    • 13.3.6.3. SWOT Analysis
    • 13.3.6.4. Financial Overview
    • 13.3.6.5. Strategic Overview
  • 13.3.7. NIHON KOHDEN CORPORATION
    • 13.3.7.1. Company Overview
    • 13.3.7.2. Product Portfolio
    • 13.3.7.3. SWOT Analysis
    • 13.3.7.4. Financial Overview
    • 13.3.7.5. Strategic Overview
  • 13.3.8. Schiller AG
    • 13.3.8.1. Company Overview
    • 13.3.8.2. Product Portfolio
    • 13.3.8.3. SWOT Analysis
    • 13.3.8.4. Financial Overview
    • 13.3.8.5. Strategic Overview

관련자료